<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048293</url>
  </required_header>
  <id_info>
    <org_study_id>326-3847-22</org_study_id>
    <nct_id>NCT02048293</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules</brief_title>
  <official_title>Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules Available in Colombia for Tracheal Intubation of Adult Patients, 2012-2013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Universitaria de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de San Jose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Universitaria de Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unbranded drug molecules are produced after the patent of a given drug has expired. Unbranded
      molecules of Remifentanil have been marketed in Colombia, and several reports by
      anesthesiologist indicate that there are differences in the physiologic response of patients
      to these molecules. The investigators hypothesized that unbranded molecules of remifentanil
      require higher doses to obtain desired physiological responses as compared to the branded
      molecule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction. Several remifentanil products are commercialized in Colombia while these have
      never been compared in a clinical setting.

      Objective. The aim of this study was to investigate the pharmacodynamic profile of the
      innovative molecule of remifentanil (group O = Ultiva®) and two unbranded molecules (group A
      = Remifentanil Laboratorios Chalver de Colombia S.A. and group B = Fada Remifentanilo)
      registered in Colombia.

      Methods. The investigators carried out a double-blind, randomized, controlled trial. The
      branded molecule of remifentanil (group O, n=29) was compared against the two unbranded
      molecules (group A, n=29; group B, n=32) during anesthetic induction and tracheal intubation
      in adult patients American Society of Anesthesiology Physical Status Classification = I
      without predictors for difficult airway. The target controlled infusion (TCI) doses evaluated
      were 6, 8 and 10 ng/ml with the Minto model. Induction was complemented with propofol 5 mg/ml
      (TCI) with the Schneider model and rocuronium 0.6 mg/kg. The primary outcome was defined as
      the difference in mean arterial pressure and heart rate pre-intubation (TCI equilibrium) and
      post-intubation (maximum measurement within 5 minutes).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of heart rate or mean arterial pressure difference before and after tracheal intubation</measure>
    <time_frame>Average of 5 minutes</time_frame>
    <description>Heart rate measured with EKG. Mean arterial pressure measured with automatic blood pressure cuff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cooper intubation condition score</measure>
    <time_frame>Measured during tracheal intubation, average of 30 seconds</time_frame>
    <description>Jaw relaxation: 0 poor, 1 minimum, 2 moderate, 3 good. Vocal cords: 0 closed, 1 closing, 2 moving, 3 open. Intubation response: 0 severe cough, 1 mild cough, 2 mild diaphragmatic movement, 3 no response.
Cooper score: Jaw relaxation + Vocal cords + Intubation response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanyl innovative molecule = Ultiva®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanyl comparator B = Fada Remifentanilo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanyl, Ultiva®</intervention_name>
    <description>Anesthetic induction for orotracheal intubation. Group O</description>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Laboratorios Chalver de Colombia S.A.</intervention_name>
    <description>Anesthetic induction for orotracheal intubation. Group A</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fada Remifentanilo</intervention_name>
    <description>Anesthetic induction for orotracheal intubation. Group B</description>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring orotracheal intubation

          -  18-50 years old

          -  Body mass index &lt;31 kg/m2

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Risk of difficult airway

          -  History of opioid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>luis e reyes, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>fundacion universitaria de ciencias de la salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Universitaria de Ciencias de la Salud, Hospital de San Jose</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Kwak HJ, Min SK, Kim DH, Kang M, Kim JY. Effect-site concentration of remifentanil for nasotracheal versus orotracheal intubation during target-controlled infusion of propofol. J Int Med Res. 2011;39(5):1816-23.</citation>
    <PMID>22117982</PMID>
  </reference>
  <reference>
    <citation>Lysakowski C, Dumont L, Pellegrini M, Clergue F, Tassonyi E. Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. Br J Anaesth. 2001 Apr;86(4):523-7.</citation>
    <PMID>11573626</PMID>
  </reference>
  <reference>
    <citation>Coskun D, Celebi H, Karaca G, Karabiyik L. Remifentanil versus fentanyl compared in a target-controlled infusion of propofol anesthesia: quality of anesthesia and recovery profile. J Anesth. 2010 Jun;24(3):373-9. doi: 10.1007/s00540-010-0898-1. Epub 2010 Mar 13.</citation>
    <PMID>20229001</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Universitaria de Ciencias de la Salud</investigator_affiliation>
    <investigator_full_name>Luis Eduardo Reyes Ortiz, MD</investigator_full_name>
    <investigator_title>Physician, Anesthesiologist, Intensive Care Specialist, Professor Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá D.C.</investigator_title>
  </responsible_party>
  <keyword>remifentanil</keyword>
  <keyword>propofol</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>total intravenous anesthesia</keyword>
  <keyword>orotracheal intubation</keyword>
  <keyword>heart rate</keyword>
  <keyword>mean arterial pressure</keyword>
  <keyword>Cooper intubation condition score</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

